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Abstract 
Abstract: Allergen immunotherapy (AIT) is the only disease-modifying treatment approved for allergic rhinitis and 
allergic asthma and represents a suitable therapeutic option, especially in childhood, to modify the progression of 
respiratory allergic diseases. Starting from the previous “generic class effect” evaluation, as testified by the numerous 
meta analyses, AIT is now considered a product-specific pathogenic-oriented treatment.
Background: AIT was empirically proposed more than one century ago in the subcutaneous form (SCIT), but the 
IgE-mediated mechanism of allergy was elucidated only after 50 years of clinical use of the treatment. The sublingual 
administration (SLIT) was developed during the 1980 ties, to achieve an improvement in safety and convenience. 
While SCIT is approved in the United States for the treatment of asthmatic patients with more than 12 years, so far 
few trials evaluated the clinical efficacy and safety of SLIT in children with allergic asthma, although the indications 
and some aspects remain unclear. Certainly, due to compliance problems, the age below 3 years may be reasonably 
considered a practical contraindication.
Conclusions: Given that some specific AIT products are effective and approved as drugs (AIFA, EMA, FDA), the use 
in children is still debated. Some aspects still need robust confirm: (a) the safety of AIT in asthma; (b) the optimal regi-
men of administration; (c) the role of AIT as preventative treatment for asthma development.
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The previous view: the efficacy of AIT as product 
class
Allergen immunotherapy is the only disease-modifying 
treatment approved for allergic rhinitis, allergic asthma 
and hymenoptera venom allergy [1]. Its use is also being 
investigated for food allergy and atopic dermatitis [2].
Allergen immunotherapy may also represent a valuable 
therapeutic option, especially in childhood, to modify 
the progression of respiratory allergic diseases [3]. This 
remains, indeed, is a unique characteristic of AIT, that is 
not shared by the standard pharmacological treatments, 
which only act on symptoms. In fact, AIT intervenes 
on the pathogenic mechanisms of the allergic disease 
themselves, by driving the immune system, through the 
exposure to increasingly higher doses of the etiological 
allergen(s), to develop a controlled immune response. 
Thus, so far AIT is the only curative treatment available 
for allergic diseases approved by the major regulatory 
authorities in the world including Food and Drug Admin-
istration (FDA) and European Medicines Agency (EMA) 
[4].
Researchers and clinicians are currently facing the era 
of the so-called “precision” or “personalized” medicine. 
In such a context, AIT is a good example of personalized 
therapeutic intervention, in which the most important 
variables for an appropriate selection of the right thera-
peutic strategy can be identified [5]. Moreover, in paral-
lel with the refined knowledge of the pathogenic bases of 
allergic diseases, AIT can guarantee the most appropriate 
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allocation of resources in this time of economical restric-
tions [6].
Allergen immunotherapy was early proposed in its sub-
cutaneous form (SCIT, subcutaneous immunotherapy) 
more than one century ago [7]. The sublingual adminis-
tration (SLIT) was later developed [8], leading to a rel-
evant improvement in safety and convenience, with less 
frequent severe adverse events. In addition, SLIT allowed 
the patient’s self-administration with a consequent 
reduction of the indirect costs.
The efficacy of AIT was grossly evaluated as a “class 
effect”. This implied that also products with a poorly dem-
onstrated scientific evidence of efficacy were included in 
meta analyses.
An example of this class effect is a study conducted 
from June 1999 to June 2000 which enrolled 159 adults 
and children with allergic asthma with multiple sensitiza-
tion to grass pollens, tree pollens, weed pollens, animal 
dander, house-dust mites and moulds. All patients were 
treated with a standardized aqueous allergen extract in 
glycerol (ORALVAC, Bencard Allergie GmbH, Munich, 
Germany) using three concentrations at 100, 1.000 and 
10.000  standardized oral units (SOU)/ml. The regimen 
began with one drop of the lowest concentration and 
ended with sixteen drops of the highest concentration. 
Following this incremental phase, a maintenance dose of 
16 drops of the 10.000 SOU/ml formulation was admin-
istered three times a week for 4–6 months. The results of 
this study showed a statistically significant reduction in 
medication for all allergens sensitizations (P =  .023) but 
the asthma “variable” was not highlighted in this study 
[9].
Several double-blind randomized placebo-con-
trolled clinical trials demonstrated the efficacy of  Lais® 
(Lofarma), a carbamylated allergoid, in patients with 
HDM-induced allergic rhinitis with or without allergic 
asthma, proving a reduction in the total and individual 
symptoms and the drug consumption [10] (Table  1). 
Another clinical trial showed a reduction in bronchial 
hyperactivity, nasal inflammation assessed by nasal 
eosinophil count and asthma and rhinitis symptoms 
score in patients treated with three different doses of this 
carbamylated allergoid vs. placebo [11]. Only one clinical 
trial evaluated Lais administration to 28 children (mean 
age 13.3 ± 2.1 year) with HDM, Parietaria and Timothy 
grass-induced allergic rhinitis and/or asthma to verify 
the occurrence of immediate adverse reactions after an 
ultra-rush regimen exposure [12]. This study showed an 
excellent safety and tolerability profile but no other data 
on Lais in allergic children are at disposition.
Another study conducted from March 2004 to June 
2005 evaluated the safety and the tolerability of an ultra-
rush method in 100 children (average age of 9.6  years) 
with allergic rhinitis, asthma, allergic conjunctivitis and 
atopic eczema. The investigators utilized standardized 
allergen extract solutions from Anallergo (Florence, Italy) 
and Staloral 300 from Stallergènes. Final data showed a 
high level of safety and tolerability for both the prepara-
tions [13].
Pollinex® Quattro (Allergy Therapeutics) is an ultra-
short course specific immunotherapy (uSCIT) vaccine 
containing glutaraldehyde-modified allergen extracts 
formulated with l-tyrosine and with the adjuvant 
monophosphoryl lipid A (MPL) administered as a pre-
seasonal course of four injections. A total of 13 seasonal 
pollen allergens are extracted and processed to form a 
series of allergoids with the following dosage scheme: 
300, 800, 2000  standardized units (SU) administered 
in a weekly 1  ml injections, followed by a further top 
dose injection of 2000  SU to complete the four injec-
tions course.  Pollinex® Quattro has been evaluated in 
3114 patients with multiple sensitization to pollens, 421 
of which were children and adolescents 6–18 years with 
seasonal allergic rhinitis, conjunctivitis and/or asthma. 
The length of this post-marketing surveillance study was 
3  years. AIT was well accepted by children/adolescents 
and considered very good or good by 93% of the juvenile 
population. After the first treatment course, antiallergic 
medication use decreased from 83 to 24% of patients 
(P < .0001). Response to treatment was assessed as good 
or very good in 94% of patients and further improve-
ments occurred in patients receiving subsequent courses 
of therapy [14].
Nowadays, it is recognized that each single product 
should be evaluated individually, as stated by the World 
Allergy Organization [15].
It is true that some issues and unmet needs remain 
critical: (a) at what age should the treatment be started? 
(b) for how many years does the treatment need to be 
maintained?; (c) does AIT really prevent the progression 
of respiratory allergy?; (d) a predictive biomarker of effi-
cacy is required [16].
AIT in children with allergic asthma
A meta-analysis by Abramson et  al. evaluated SCIT in 
allergic asthmatic patients, both adults and children. 
Overall, the results showed a significant clinical efficacy 
based on the standard parameters (symptoms, rescue 
medications usage, quality of life) [17]. Other available 
studies on the use SLIT in asthmatic children with mild 
to moderate HDM-induced asthma showed signifi-
cant efficacy mainly in the reduction of symptoms and 
medication usage [18, 19]. The more recent clinical tri-
als in children with birch pollen and grass pollen allergic 
asthma, further confirmed the efficacy of SLIT in such 
conditions [20, 21].
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According to the more recent evidence, the interna-
tional asthma documents now recommend a supportive 
role of AIT, as add on treatment to the standard of care 
[22]. Uncontrolled asthma remains an absolute contrain-
dication for AIT [23].
The main and relevant aspect of AIT in children is 
the possible role of the treatment in reducing the risk 
of asthma onset and of new allergen sensitizations [24]. 
Children sensitized to one single allergen, as usually hap-
pens, when treated with AIT seem to develop new sen-
sitizations at a lesser extent, but this is still matter of 
debate since the evidence remains poor [25, 26].
On the other hand, there were some randomized open 
clinical trials (one with SCIT and two with SLIT) show-
ing a preventive effect to decrease the risk of asthma 
onset in allergic children with rhinitis. This phenomenon 
was recently confirmed in a randomized and double pla-
cebo controlled trial, showing that 2  years after discon-
tinuation of AIT, there was a reduction in symptoms and 
medication usage [27].
The current view: evaluation of the “single 
product”
At present, the efficacy of AIT is no longer considered 
as a generic “class effect” and each AIT product is evalu-
ated according to its scientific evidence (Table 2). This led 
to the approval of single AIT preparations by EMA and 
FDA [28].
In 2006 a total of 855 patients with grass pollen 
induced allergic rhinoconjunctivitis were randomized 
to placebo or 2.500, 25.000 or 75.000 once daily stand-
ardized quality (SQ)—grass allergen sublingual tablets 
 (Grazax®/Grastek®; ALK-Abelló, Hørsholm, Denmark). 
This pivotal trial showed a dose-related response with 
highest reductions in symptoms and medication utiliza-
tion and improvements in quality of life (QoL) for the 
75.000 SQ-T tablet [29]. Further studies confirmed these 
results in children [30].  Grazax®/Grastek® is currently 
indicated for children  >  5  years and adults with allergic 
rhino conjunctivitis (Table 1).
Oralair® (Stallergenes, France) is a mixture of natural 
allergens of pollens from five cross-reacting grasses (Dac-
tylis glomerata L., Anthoxanthum odoratum L., Lolium 
perenne L., Poa pratensis L. and Phleum pratense L.). 
 Oralair® is approved in Europe and the US for the treat-
ment of grass pollen induced ARC in children > 5 years 
(>  10  years in the US) and adults with confirming skin 
prick testing and/or specific IgEs [31].
In 2007 Didier et  al. conducted a randomized clini-
cal trial evaluating the dose–response efficacy with a 
pre-coseasonal  Oralair® in 628 patients showing clinical 
benefits in patients receiving 300 and 500 index of reac-
tivity (IR) 2–4 months before season-start over placebo. 
Consequently, the 300 IR dose (25  μg of group 5 grass 
pollen major allergen) providing a significant reduction 
in symptoms, was selected as the optimal dose for com-
mercialization [32, 33] (Table 1).
Purethal® Mites (HAL Allergy) is a mite extract mix-
ture used at a concentration of 20,000 AUeq/ml (8 μg/ml 
of Der p1 and 30  μg/ml of Der p2). The administration 
schedule contemplated a build-up weekly-based phase 
of increasing doses (1000, 2000, 4000, 6000, 8000 and 
10,000  AUeq), whereas the maintenance phase involved 
the injection of 10,000  AUeq (Der p1, 4  μg of Der p1 
and 15 μg of Der p2) at monthly intervals. A total of 43 
asthmatic children (6–14 years) with mites sensitization 
were divided in two groups: 23 individuals were treated 
with subcutaneous  Purethal® for 8 months and 20 were 
the control group. In the active group, there was an 
improvement in overall asthma classification and severity 
(P < .001 compared to baseline), a reduction in drugs use 
and an improvement in quality of life over time during 
the follow-up [34].
Staloral® 300 (SLIT with IR (index of reactivity)-stand-
ardized D. pteronyssinus  +  D. farinae extract (300  IR/
mL) manufactured by Stallergenes), has been tested in 
children aged 6–18 with allergic rhinitis with or without 
allergic asthma [27]. All patients treated with  Staloral® 
reported improved rhinitis and/or asthma symptoms 
scores, together with a reduction in the as-needed drug 
for breakthrough symptoms, with no significant differ-
ences in FEV1 and Peak Flow [35] (Table 1).
Another house dust mite sublingual preparation (MK-
8237) has been approved for patients with HDM-induced 
ARC with or without coexisting asthma [36] (Table 1).
The product, a standardized allergen extract from 
D. pteronyssinus and D. farinae 12 SQ-HDM* per oral 
lyophilisate, has been approved in 2015 by EMA with the 
brand name of  Acarizax® for Europe, Canada and Aus-
tralia (ALK-Abelló, Hørsholm, Denmark), and it is the 
first SLIT preparation approved in Europe for the treat-
ment of allergic asthma. In fact, in February 2017 the 
Global Initiative for Asthma (GINA) for the first time 
added AIT as a treatment option in its guidelines [22]. 
Originally approved only for patients  >  18  years old, 
 Acarizax® was recently approved also for adolescent 
patients with house dust mite-induced allergic rhinitis 
in Austria, Czech Republic, Denmark, Finland, Italy, the 
Netherlands, Norway, Poland, Sweden, Slovakia, France 
and Germany [37].
MK-8237 has been approved in September 2015 by the 
Japanese Ministry of Health, Labour and Welfare under 
the name of  Miticure® (Torii Pharmaceutical Co., Japan), 
at a dose of 3300 Japanese Allergen Units (JAU) once a 
day during the 1st  week of treatment and one tablet of 
 Miticure® 10,000 JAU once a day from the 2nd week for 
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adults and children aged ≥ 12 years [38] (Table 1). Nowa-
days, since there are no indications of MK-8237 utiliza-
tion in children so far, the Company is running a Phase 
III clinical trial in patients aged 5–11 years [39].
The efficacy of this preparation in asthmatic patients 
was demonstrated in three clinical trials, two of which 
included also adolescents.
Mosbech and colleagues, enrolled 604 subjects includ-
ing adolescents aged > 14 years with HDM-induced aller-
gic rhinitis and mild-to-moderate asthma. These subjects 
were randomized in 1:1:1:1 to double-blind daily treat-
ment with active doses (1, 3, or 6 SQ—HDM) or placebo. 
The main outcome was a steroid-sparing effect which 
resulted dose-dependent, higher in subjects receiv-
ing 6 SQ HDM-SLIT tablets and that mild-to-moderate 
HDM-sensitized asthmatic patients could significantly 
benefit from specific immunotherapy [40]. Furthermore, 
MK-8237 was evaluated in a recent north American clini-
cal trial (NCT01700192) in adolescents aged 12 years old 
with HDM-induced allergic rhinoconjunctivitis with or 
without asthma. This trial confirmed the results obtained 
by the previous European trials [41].
So far, only one trial to evaluate the clinical efficacy and 
safety of SLIT in children is still in progress [39]. Thus 
the need for more robust data in such a population is 
emergent.
Indications and patients’ selection
Definite indications for the use of AIT in children with 
asthma are still not fully clarified [16]. Most guidelines 
[24] agree that AIT is not contraindicated in children 
with mild to moderate allergic asthma, but also state that 
asthma must be fully controlled by the standard of care 
pharmacological treatment, when AIT is prescribed [16, 
17, 42, 43]. The recent ARIA guidelines [44] suggest both 
SCIT and SLIT as a conditional recommendation in aller-
gic asthma, due to the moderate/low quality of evidence. 
The lack of robust evidence led to a certain grade of 
opposition to the use of AIT in asthmatics [45]. Indeed, 
the potential benefits of AIT must be weighed against the 
risk of adverse effects, the inconvenience and cost of a 
prolonged course of therapy, as stated by the 2017 Global 
Initiative for Asthma Report [46] considering also other 
factors such as poor adherence, clinically non relevant 
allergens, poly-sensitizations, unavoidable adverse reac-
tions of routine medication, etc [47].
Contraindications
So far, according to literature, absolute contraindica-
tions to AIT involve serious immunologic diseases, major 
cardiovascular diseases, cancer, chronic infections, lack 
of compliance and severe psychological disorder [23]. 
Eosinophilic esophagitis remains an absolute contraindi-
cation to SLIT [48].
Relative contraindications include any condition that 
would reduce the patient’s ability to survive a potential 
systemic allergic reaction [42]. Temporary contraindica-
tions are limited to acute infections and, for SLIT, to oral 
acute inflammation, injury or surgical intervention or 
acute gastroenteritis [4, 48–50].
Well-controlled asthma, independently from its sever-
ity, is not an absolute contraindication to AIT [23], 
whereas uncontrolled asthma is an absolute contrain-
dication due to the risk of serious or even fatal adverse 
reactions [23, 47, 51]. In this context, the pre-treatment 
with omalizumab [52] has been suggested as a suitable 
option to increase the safety. Partially controlled asthma 
is considered a relative contraindication in the EAACI 
paper and the German guidelines open to the possibil-
ity of use of AIT in these patients [48]. An open area of 
debate regards well controlled severe asthma, which 
would not meet the EAACI definition of contraindica-
tion, but for which more evidence should become avail-
able before recommendations can be issued.
Age of AIT initiation
The age of 3  years is considered a reasonable contrain-
dication, due to the poor adherence and side effects [53] 
and age below 5  years is listed as a relative contraindi-
cation to AIT in most documents [23, 49, 54], although 
there are positive reports in such age range [55–58]. The 
reasons for this choice can be found in the limited evi-
dence [59] and for practical reasons, but this issue may 
deserves more in-depth studies in the perspective of pre-
ventive strategies. In fact, a recent position paper by the 
SIAIP (Società Italiana di Allergologia e Immunologia 
Pediatrica) [43] recommends the consideration of AIT as 
a therapeutic option also in preschool age.
Administration regimen, duration of treatment 
and adherence
While there is a universal consensus about administra-
tion regimen for SCIT, with the maintenance phase given 
as one injection every 4  weeks, the best SLIT mainte-
nance regimen has not been defined yet [16]. The rec-
ommended regimens would favour the pre-coseasonal 
administration vs. the continuous one, at least for sea-
sonal allergens [60, 61].
It is usually recommended that at least 3 years of treat-
ment are necessary to achieve and maintain clinical ben-
efit [4, 48–50]. A prolonged remission of symptoms is 
described in many patients [62–66], while others may 
experience a relapse after discontinuation. As for adults, 
it is still not clear in pediatric populations whether treat-
ment continuation beyond 3 years leads to persistence of 
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clinical benefit after discontinuation [29, 62, 64, 67] and if 
other factors are involved. The decision about the dura-
tion of treatment remains on the clinician judgment, who 
should take into account the patient clinical response, 
disease severity, adverse events and patient’s preference 
[42]. In fact, adherence to therapy is an important issue, 
due to the long duration of treatment [68]. It was shown 
that 64.6% of children was unable to complete 3  years 
of therapy [69]. The reported major factors involved in 
non-compliance were the cost of treatment, the incon-
venience of injections for SCIT and the daily necessity of 
assumption for SLIT and local reactions [70, 71].
Safety
Adverse reactions to AIT can be divided in local (limited 
to the site of administration) [72] and systemic (wheez-
ing, urticaria, anaphylaxis, fatal reactions) [17]. Local 
reactions consist mainly in local itching and/or edema 
and, only for SLIT, gastrointestinal complains [46].
Systemic reactions are more frequent in SCIT, for 
which the reported incidence varies between .06 and 
1.01% [73], whereas with SLIT systemic reactions are 
reported to occur quite rarely [74].
In a recent prospective European survey [75] involv-
ing 762 children and 801 adolescents undergoing AIT, a 
total of 29 reactions have been reported, of which 23 dur-
ing SCIT and 6 during SLIT, comprising 3 cases of ana-
phylaxis, all related to SCIT. Interestingly, the reported 
cases of anaphylaxis all had a delayed onset (> 2 h after 
administration), which highlights an open issue about the 
correct duration of patient observation after AIT admin-
istration, that should last at least 30  min according to 
current recommendations [49, 50]. Sublingual adminis-
tration appears to be correlated with a much lower risk 
of systemic reactions. A 2009 observational study in 193 
children receiving SLIT [76] reported nearly 500 mild 
local reactions and only one systemic reaction consist-
ing in a severe asthma attack and a recent review of 80 
double-blind placebo-controlled trials concluded that in 
most studies the incidence of systemic reactions was sim-
ilar in the treatment group and the placebo group [46].
The occurrence of adverse reactions depends on several 
factors, including human errors, extracts used, adminis-
tration route, schedule and the dose administered [52]. 
Patient-related factors comprise, as already stated, the 
presence of asthma, especially if uncontrolled [23], pol-
ysensitization and grass pollen sensitization [75]. The 
administered dose seems to be related to systemic reac-
tions only in SCIT, while this does not appear to be dose-
dependent with SLIT [47].
Conclusions and expert opinion
Allergen immunotherapy remains a cornerstone option 
for the treatment of respiratory allergy and for hymenop-
tera venom allergy with a promising extension to food 
allergy. AIT especially in the sublingual administration, 
remains a suitable option in children since it can be eas-
ily managed at home, although some aspects still need to 
be experimentally defined [77]. The possible use of AIT 
as primary prevention still remains a matter of debate, 
whereas the clinical efficacy in children is well ascer-
tained, at least for some specific products [78]. Asthma, 
when well controlled does not represent an absolute con-
traindication to AIT. There is a consistent evidence that 
AIT can reduce the risk of asthma onset in sensitized 
children.
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